VascuStim

VascuStim is a clinical-stage biotechnology company focused on developing regenerative therapies for severe vascular diseases, specifically chronic limb-threatening ischemia (CLTI). The company's lead technology, the VascuStim System, is a proprietary point-of-care platform designed to concentrate and deliver autologous bone marrow-derived mononuclear cells (BM-MNCs) directly into ischemic tissues. This therapeutic approach aims to stimulate angiogenesis and restore blood flow in patients who have exhausted traditional surgical and endovascular treatment options. By leveraging the body's own regenerative potential through a rapid, bedside processing system, VascuStim seeks to prevent limb amputations and improve patient outcomes. The company is currently advancing its lead program through Phase 1/2 clinical trials in the United States.